Bacillus Calmete-Guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 5, 2003, Pages 354-360

  Lam, John S ^a   Benson, Mitchell C ^a   O'Donnell, Michael A ^b   Sawczuk, Alexandra ^c   Gavazzi, Anna ^a   Wechsler, Michael H ^a   Sawczuk, Ihor S ^a,c  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bacillus Calmette Gu rin; Bladder neoplasms; Interferon 2B; Therapeutics; Toxicity

Indexed keywords

BCG VACCINE; RECOMBINANT ALPHA2B INTERFERON;

ARTHRALGIA; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; MORBIDITY; PRIORITY JOURNAL; SIDE EFFECT; SUPERFICIAL CANCER; TUMOR BIOPSY;

AGED; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 2042421499     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00012-7     Document Type: Article

References (33)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer Statistics, 2002. CA Cancer J Clin. 52:2002;23-47
2. Messing E.M., Catalona W. Urothelial tumors of the urinary tract. Walsh P.C., Retik A.B., Vaughn E.D., Wein A.J. Campbell's urology. 7th ed:1998;2327-2410 WB Saunders Co, Philadelphia. Chap 77
3. Dalbagni G., Herr H.W. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am. 27:2000;137-146
4. Herr H.W. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors 15-year outcome. J Urol. 163:2000;60-62
5. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer Ten-year follow-up of a prospective randomized trial. J Clin Oncol. 13:1995;1404-1416
6. Nseyo U.O., Lamm D.L. Therapy of superficial bladder cancer. Semin Oncol. 23:1996;598-604
7. Morales A., Ottenhof P., Emerson L. Treatment of residual noninfiltrating bladder cancer with bacillus Calmette-Guerin. J Urol. 125:1981;649-651
8. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209
9. Herr H.W., Pinsky C.M., Whitmore W.F., Sogani P.C., Oettgen H.F., Melamed M.R. Long term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol. 135:1986;265-267
10. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 19:1992;573-580
11. Vegt P.D.J., Witjes J.A., Witjes W.P., et al. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol. 153:1995;929-933
12. Lamm D.L. Carcinoma in situ. Urol Clin North Am. 19:1992;499-508
13. Lamm D.L. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am. 19:1992;565-572
14. Glashan R.W. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol. 144:1990;658-661
15. Belldegrun A.S., Franklin J.R., O'Donnell M.A., et al. Superficial bladder cancer The role for interferon alfa. J Urol. 159:1998;1793-1801
16. Williams R.D., Gleason D.M., Smith A.Y., et al. Pilot study of intravesical alfa-2b interferon for treatment of bladder carcinoma in situ following BCG failure. J Urol. 155:1996;494A-735A. [Abstract]
17. Stricker P., Pryor K., Nicholson T., et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology. 48:1996;957-962
18. Bercovich E., Deriu M., Manferrari F., Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl. 67:1995;257-260
19. O'Donnell M.A., Krohn J., DeWolf W.C. Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 166:2001;1300-1305
20. Esuvaranthan K., Kamaraj R., Mohan R.S., et al. A phase IIB trial of BCG combined with interferon alpha for bladder cancer. J Urol. 163:2000;152A-675A. [Abstract]
21. Pagano F., Bassi P., Piazza N., Abatangelo G., Drago Ferrante G.L., Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol. 27:(Suppl 1):1995;19-22
22. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance BCG immunotherapy in recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma A randomized Southwest oncology Group study. J Urol. 163:2000;1124-1129
23. Nadler R.B., Catalona W.J., Hudson M.A., et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 152:1994;367-373
24. Martinez-Pineiro J.A., Solsona E., Flores N., et al. Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur Urol. 27:(Suppl 1):1995;13-18
25. Morales A., Nickel J.C., Wilson J.W. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol. 147:1992;1256-1258
26. Mack D., Frick J. Five-year results of a phase II study with low-dose BCG therapy in high-risk superficial bladder cancer. Urology. 45:1995;958-961
27. Mack D., Holtl W., Bassi P., et al. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol. 165:2001;401-403
28. A Northern California Oncology Group Study, Torti F.M., Shortliffe L.D., Williams R.D., et al. Alpha-interferon in superficial bladder cancer. J Clin Oncol. 6:1988;476-483
29. Hoeltl W., Hasun R., Albrecht W., Marberger M. How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer? Brit J Urol. 68:1991;495-498
30. Catalona W.J., Hudson M.A., Gillen D.P., Andriole G.L., Ratliff T.L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 137:1987;220-224
31. The Valrubicin Study Group, Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 163:2000;761-767
32. Swedish-Norwegian Bladder Cancer Study Group, Malmstrom P.U., Wijkstrom H., Lundholm C., Wester K., Busch C., Norlen B.J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol. 161:1999;1124-1127
33. Luciani L.G., Neulander E., Murphy W.M., Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer An investigational approach. Urology. 58:2001;376-379